Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.
Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.
Matthew Matasar, MD, shares...